An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
Public ClinicalTrials.gov record NCT05514873. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Participants With Generalized Myasthenia Gravis Switching From Intravenous Complement Component 5 Inhibitors to Subcutaneous Zilucoplan
Study identification
- NCT ID
- NCT05514873
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Enrollment
- 26 participants
Conditions and interventions
Conditions
Interventions
- zilucoplan (RA101495) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 30, 2022
- Primary completion
- Mar 12, 2024
- Completion
- Oct 22, 2024
- Last update posted
- Sep 2, 2025
2022 – 2024
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mg0017 50564 | Scottsdale | Arizona | 85251 | — |
| Mg0017 50559 | Los Angeles | California | 90095 | — |
| Mg0017 50593 | Rancho Mirage | California | 92270 | — |
| Mg0017 50099 | San Francisco | California | 94143 | — |
| Mg0017 50557 | O'Fallon | Illinois | 62269 | — |
| Mg0017 50556 | Chapel Hill | North Carolina | 27599 | — |
| Mg0017 50086 | Charlotte | North Carolina | 28207 | — |
| Mg0017 50076 | Columbus | Ohio | 43221 | — |
| Mg0017 50555 | Austin | Texas | 78759 | — |
| Mg0017 50304 | Dallas | Texas | 75390-8866 | — |
| Mg0017 50111 | Seattle | Washington | 98195-0001 | — |
| Mg0017 50569 | Greenfield | Wisconsin | 53228 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05514873, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 2, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05514873 live on ClinicalTrials.gov.